Form 4: Immunocore Holdings CEO Granted Stock Options and Restricted Share Units

CEO of Immunocore Holdings, Bahija Jallal, receives stock options and restricted share units as part of compensation.

Summary

• Bahija Jallal, CEO of Immunocore Holdings plc, was granted stock options and restricted share units on February 17, 2025.
• The stock options grant covers 405,824 ordinary shares with an exercise price of $29.60.
• 25% of the options vest on February 17, 2026, with the remaining 75% vesting quarterly thereafter, contingent upon continued service.
• The options expire on February 16, 2035.
• Additionally, 95,270 restricted share units (RSUs) were granted, each representing a contingent right to receive one ordinary share.
• The RSUs vest in four equal annual installments beginning February 17, 2026, also subject to continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options and RSUs aligns the CEO's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedules encourage continued service and commitment from the CEO.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Immunocore Holdings' stock price.
• If the CEO leaves the company before the vesting dates, a portion or all of the unvested options and RSUs may be forfeited.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the equity grants.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain top executive talent and align their interests with those of shareholders. The size and structure of the grants are likely benchmarked against peer companies.

Comparison to Industry Standards

• Equity compensation packages for CEOs in the biotechnology industry typically include a mix of stock options and restricted stock units.
• The vesting schedules are generally structured to incentivize long-term performance and retention, often over a period of 3-4 years.
• Companies like Amgen, Gilead, and Regeneron also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the CEO's interests with the company's long-term success.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates